GLOW Peptide Dosage Calculator & Protocol

GLOW is a skincare tool. For reactive or inflammation-prone skin, KLOW adds KPV to calm the field before the architectural work lands; for soft-tissue injury, the injury protocols (or the Wolverine Stack) are the right tools.

GLOW Peptide Dosing

GLOW anchors on 2 mg GHK-Cu per injection, daily, subcutaneous — collagen and matrix quality is the whole job. Reconstitute the 70 mg vial with 2.5 mL BAC water and draw 0.1 mL (10 units on a U-100 insulin syringe) for each dose. Cycle 8–12 weeks active, then 4–8 weeks off (or step down to 2–3× weekly maintenance). The other two peptides come along at fixed proportions; the calculator above solves any custom anchor.

What's in a GLOW Vial

A standard 70 mg GLOW blend vial contains three peptides in fixed mass ratios: 50 mg of GHK-Cu, 10 mg of BPC-157, and 10 mg of TB-4. GHK-Cu carries 71% of vial mass — collagen synthesis is the continuous daily demand the protocol is built around. Per-dose protocol is summarized in the At a Glance above; the GLOW Calculator solves any custom anchor.

Cycle the cocktail as a whole: 8–12 weeks active, then 4–8 weeks off (or step down to 2–3× weekly maintenance).

Note: at GLOW's per-dose range, TB-4 lands at 400 mcg per injection — background tissue-organization signaling that supports the matrix work, not injury-grade migration dosing. That is by design: GLOW is a skincare tool built around skin's continuous collagen demand. Soft-tissue injury needs the higher repair doses and TB-4 bolus the fixed ratio cannot deliver — the injury protocols are the right path.

GLOW compounds

• GHK-Cu — Builds new collagen and clears damaged tissue at the same time (copper-peptide signaling, lysyl oxidase cross-linking¹). Most collagen interventions only do the second; the protocol is built around this compound.
• BPC-157 — Sprouts new small blood vessels into the dermal repair area (angiogenic signaling²). Without that capillary supply, GHK-Cu has the signal but no nutrient delivery to the treatment site.
• TB-4 (full-length thymosin β4, 43 aa) — Moves repair cells (fibroblasts) into position and biases healing toward functional tissue rather than rope-like scarring (G-actin sequestration³, Ac-SDKP anti-fibrotic fragment⁴).

GLOW predates KLOW, which adds KPV as a fourth peptide for users with reactive, post-procedure, or actively inflamed skin. The shared three peptides sit at identical masses; switching mid-cycle is just a vial swap.

GLOW is not FDA approved and no controlled trial has evaluated the blend — but absence of a blend trial is not absence of evidence. The FDA model approves single-intervention single-endpoint drugs; GLOW is a three-compound cocktail of mostly unpatentable peptides, so no sponsor will fund a multi-phase trial of the formulation. That is an economics problem, not a safety verdict. BPC-157's status is unsettled rather than rejected — the 2026 FDA Category 2 removal and the July 2026 PCAC review are access context, not a therapeutic rejection. The component-level human evidence is in the evidence table below.

The dosing below draws from the per-component research and a decade of practitioner protocols — informed direction, not a result the blend has been formally measured against.

For mechanism depth on each peptide, see the standalone guides: GHK-Cu, BPC-157, TB-500 / TB-4. The full mechanism, supporting factors, and evidence base are further down this page.

GLOW Dosing Protocol

GLOW anchors on GHK-Cu — collagen and matrix quality is the whole job, and the other two peptides come along at fixed proportions. GHK-Cu drives collagen rebuilding; BPC-157 holds up blood flow to the repair area; TB-4 biases healing toward functional tissue over scarring (Ac-SDKP anti-fibrotic action).

The 2 mg GHK-Cu anchor lands on a clean 10-unit daily draw on a U-100 insulin syringe. Use the GLOW Dosage Calculator above to solve any custom dose or vial size.

GLOW with skincare anchor: 2 mg GHK-Cu daily

GHK-Cu turns on collagen production at the gene level — the work that defines GLOW. Target dose: 2 mg GHK-Cu per injection, daily, subcutaneous.

With 50 mg GHK-Cu in the vial and a 2 mg per-dose target, 2.5 mL BAC water gives you:

$$V_{\text{draw}}=\frac{2\text{ mg}\times 2.5\text{ mL}}{50\text{ mg}}=0.1\text{ mL}=10\text{ units on U-100 syringe}$$

• Reconstitute with 2.5 mL BAC water → 0.1 mL (10 units on a U-100 insulin syringe) delivers 2 mg GHK-Cu
• If you have a larger vial (5 mL), reconstitute with 5 mL → 0.2 mL (20 units) per dose — more volume to inject but cleaner syringe read and reduced concentration-dependent sting.

Skincare — Per-dose payload: 2 mg GHK-Cu, 0.4 mg BPC-157, 0.4 mg TB-4.

One 70 mg vial of GLOW lasts 25 daily doses at the 2.5 mL reconstitution — well inside the 28-day refrigerated stability window.

GHK-Cu's collagen-gene regulation pairs with overnight dermal repair, so evening dosing is the common default. Standard cycle: 12 weeks active, then 4–8 weeks off (or stepped down to 2–3× weekly maintenance). Indefinite daily dosing isn't the default — pulsed maintenance keeps the repair signal present without blunting the response.

Three-phase frequency taper (same per-injection dose throughout):

Expect visible texture and tone improvement by week 3–4, fine lines softening by 4–6, structural firmness and scar remodeling by 8–12.

GLOW practitioners often pair the protocol with cycled topical actives (retinoids, vitamin C, niacinamide) during the on-cycle weeks. The injectable handles dermal architecture; topicals handle surface-layer turnover and pigmentation.

Phasing and lifestyle inputs are covered in Supporting Factors below.

GLOW is skincare-only — for injury, use the injury protocols

GLOW has no injury protocol. The fixed 50/10/10 skincare ratio underdoses what soft tissue actually needs: TB-4 lands far below its cell-migration threshold, there is no KPV to gate inflammation, and BPC-157 sits at the low end of its repair range. Pushing the dose to fix any one of those overdoses GHK-Cu.

For soft-tissue injury, dose the compounds individually instead. The BPC-157 + TB-500 Wolverine Stack covers simple repair; the Injury Recovery Protocol is the five-compound version with the full-length TB-4 bolus (2–4 mg, 2–3× weekly) and NAD+ that the cocktail can't carry. For reactive or inflamed skin rather than injury, KLOW adds KPV.

How GLOW Works

Skin aging is several systems slowing at once: collagen genes firing less, the capillary supply thinning, and repair cells losing coordination. GLOW assigns one peptide to each bottleneck. Run any one alone and the gap the missing peptide would have covered becomes the rate-limiter for the whole protocol.

GHK-Cu: collagen and structure

GHK-Cu is a copper-binding tripeptide mapped across more than 4,000 genes — collagen synthesis, antioxidant defense, and wound-healing programs trend up, while inflammation and tissue-breakdown programs trend down¹. Circulating levels fall with age, from roughly 200 ng/mL at 20 to about 80 ng/mL by 60¹. It does the thing most collagen interventions skip: it clears damaged matrix as well as laying down new collagen, which is why old scars and sun damage remodel rather than sitting under a fresh layer. The copper it carries is also what turns the solution blue and produces the brief sting on injection.

BPC-157: blood supply

BPC-157 is a 15-amino-acid fragment from gastric juice. It builds the capillary network active regeneration depends on (new blood vessel formation²) and stabilizes tissue barriers so new tissue holds instead of breaking down. Without blood flow to the dermis, GHK-Cu has the signal but the raw material never reaches the work. Tone and color even out as the microvascular network fills in.

TB-4: cell migration

Full-length thymosin beta-4 (43 amino acids) governs how repair cells move into tissue and organize once they arrive (G-actin sequestration³). It biases healing toward functional tissue over rope-like scarring (Ac-SDKP anti-fibrotic signaling⁴) and calms blood-vessel cells, which shows up as less redness. GLOW uses the full-length parent, not the shorter TB-500 fragment sold for injury repair; the two are blurred on labels routinely⁵, so confirm what sequence is in the vial.

Conditional Add-Ons

NAD+ is the primary stacking support for GLOW. GHK-Cu-driven fibroblast remodeling and collagen synthesis are energy-expensive — NAD+ supplies the cellular energy and repair substrate that rebuilding spends. Run it alongside GLOW from the start under any metabolic load (GLP-1 use, caloric deficit, chronic fatigue, or age-related NAD+ decline), and it is the first add when progress plateaus at week 4–6. 100–200 mg IM, 2–3× weekly — different syringe, different site, since NAD+ is acidic and degrades peptides on contact.

GLOW alone handles standard skin quality. The remaining layers are conditional — added only when a specific bottleneck shows up, not by default:

• Topical GHK-Cu / AHK-Cu + minoxidil — Add for hair shedding during GLP-1 use or aggressive dieting. Either copper peptide alone works if availability or tolerance is a constraint. Fix the underlying deficit too — hair follicles need direct scalp exposure plus enough protein and calories to grow.
• MT-I (afamelanotide), not MT-II — Add when pigment with photoprotection sits alongside skin-quality goals. MT-II's central nervous-system side effects make it the wrong default.
• Sermorelin/ipamorelin — Add only for the growth-hormone-deficiency pattern (poor sleep + low recovery). Not a default layer.
• Switch to KLOW — When inflammation emerges or baseline reactivity is the limit. Don't run standalone KPV alongside GLOW continuously — that's KLOW with more handling steps.

Tell FoxAI your situation and it builds the right stack→

Phenotype Considerations

• Perimenopausal users. Estrogen-driven collagen decline accelerates during perimenopause, and substrate is typically already more depleted at baseline. Plan for a 12-week activation phase rather than 8.
• Recent surgery. Defer at least two weeks after major surgery. Excessive angiogenesis during early surgical healing can complicate scar formation.
• GLP-1 users / aggressive cutting. Rapid weight loss outpaces the skin's ability to remodel, and substrate availability tightens. Add NAD+ from the start; consider the topical hair overlay if shedding emerges.

Supporting Factors

Optional adjuncts: red-light therapy (630–670 nm) for 10–20 minutes daily, and microneedling every three to four weeks during Phase 2.

Safety & Considerations

• Active malignancy or cancer history within the past five years. GHK-Cu, BPC-157, and TB-4 all promote new blood-vessel formation — a hard contraindication during active cancer treatment, and a caution within five years of remission given the theoretical risk of supporting tumor blood supply.
• Wilson's disease or copper overload. GHK-Cu delivers 50 mg copper-bound peptide per vial; contraindicated in anyone with copper-handling disorders.
• Pregnancy or breastfeeding. No safety data for any of the three peptides during pregnancy.
• WADA-tested athletes. TB-4 is on the prohibited list; GLOW is not usable in-competition.
• Reactive or rosacea-prone skin. GLOW does not address inflammatory tone; KLOW is the better tool for these cases.
• Baseline photos if skincare is the goal. Progress on skin is gradual; week-0 photos are the only reliable progress marker at week 6.

The realistic alternative isn't placebo. It's topical retinoids working at the surface layer, in-office collagen-induction procedures with downtime and recurring cost, or untreated continued decline (about 1% collagen loss per year after age 30). GLOW addresses the dermal architecture below where topicals reach.

What Evidence Exists

No controlled trial has evaluated GLOW as a blend. Synergy is inferred from the individual mechanisms, not demonstrated in combination.

FAQ

Related Topics

• KLOW Dosing Calculator — The 4-peptide variant with KPV for reactive or post-procedure skin
• Injury Recovery Peptide Protocol — Five-compound structural repair framework including NAD+ metabolic support
• BPC-157 + TB-500 Wolverine Stack — Simpler injury recovery stack centered on the two core repair peptides
• BPC-157 Guide — Standalone dosing, pharmacokinetics, oral vs injectable
• TB-500 / TB-4 Guide — Fragment vs full-length, CoA verification, threshold-saturation mechanism
• GHK-Cu Guide — Copper peptide mechanism for skin and matrix quality
• NAD+ Guide — Cellular energy support for intensive repair cycles
• Peptide Reconstitution Guide — General bacteriostatic water and syringe handling
• Where to Inject Peptides — Near-injury vs systemic injection routing

References

¹ GHK-Cu tissue-organization signaling and copper-peptide complex — TGF-β/Smad matrix organization, lysyl oxidase cross-linking, SOD/catalase antioxidant expression, copper coordination chemistry, 4,000+ gene modulation: PubMed 29986520; age-related plasma decline (roughly 200 ng/mL at age 20 to about 80 ng/mL by 60): Pickart L, Margolina A. Int J Mol Sci 2018. DOI: 10.3390/ijms19071987

² BPC-157 angiogenic signaling — VEGFR2–Akt–eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860

³ TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism — actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423

⁴ TB-4 Ac-SDKP anti-fibrotic fragment — N-terminal tetrapeptide (fragment 1–4) released by meprin-α and POP processing; suppresses TGF-β-driven fibrosis and cardiac/renal remodeling: PMC4889319; fragment-specific activity review: PMC8724243

⁵ TB-4 / TB-500 product mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed peptide products: Esposito M et al. Drug Test Anal 2012. PubMed 22962027

⁶ TB-4 Phase 1 human safety — first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin β4 in healthy volunteers, no serious adverse events: PubMed 34346165; intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223–229): NCT00743769